EuroBiotech—More Articles of Note

Newspapers
(NS Newsflash/CC BY 2.0)

> Affibody raised SEK 200 million ($24 million) in a rights issue. The Swedish biotech will use the cash to expand its clinical program. Release

> Roche became the latest biopharma to team up with BioMed X. The agreement will lead to the creation of an immune-mediated disease research group in Germany. Statement

> The U.K. committed cash to create cell and gene therapy centers designed to establish it as a go-to location for clinical trials for the emerging classes of medicine. Release 

Whitepaper

Overcoming Risk in Oncology Drug Development

Oncology drug development is full of potential obstacles and risks, and you must carefully plan each step. Download this whitepaper for tips on finding the fast track. Premier Research. Built for Biotech.

> Kinase inhibitor startup BCI Pharma raised cash to advance research projects in cancer, neuropathic pain, inflammation and neuro-inflammation. Statement

> Amryt Pharma licensed a non-viral gene therapy platform. The biotech plans to explore the use of the platform in the treatment of recessive dystrophic epidermolysis bullosa. Release

> The Norwegian National Ethics Board rejected BerGenBio’s request for retrospective approval of a phase 1/2b trial of AXL kinase inhibitor BGB324. The ongoing trial only involves sites in the U.S and is FDA cleared, leaving BerGenBio unsure of the implications of the ethics snafu in its home country. Statement

Suggested Articles

The public financing will enable Monopar to start a phase 3 trial of a prophylactic treatment for a side effect of chemoradiotherapy. 

The dispute centers on whether Asa Abeliovich used Alector’s confidential information in connection with his work for Prevail Therapeutics.

GSK poaches Merck KGaA's Martinez-Davis to helm pharma stateside; Bulto named Novartis U.S. pharma head; Allergan's Saunders set for huge parachute.